




Review

Association between Childhood Onset Inflammatory Bowel Disease and Psychiatric Comorbidities in Adulthood

Andreea Sălcudean ¹, Andreea Georgiana Nan ^{2,*} , Cristina Raluca Bodo ³, Marius Cătălin Cosma ⁴, Elena Gabriela Strete ^{5,*}  and Maria Melania Lica ¹ 

¹ Department M2, Discipline of Bioethics, Social & Human Sciences, University of Medicine and Pharmacy, Sciences and Technology George Emil Palade of Targu Mures, 540142 Targu Mures, Romania

² First Department of Psychiatry, Clinical County Hospital of Targu Mures, 540142 Targu Mures, Romania

³ Second Department of Psychiatry, Clinical County Hospital of Targu Mures, 540142 Targu Mures, Romania

⁴ Pediatric Cardiology Department, Institute of Cardiovascular Diseases and Cardiac Transplantation of Targu Mures, 540136 Targu Mures, Romania

⁵ Department M4, Discipline of Psychiatry, University of Medicine and Pharmacy, Sciences and Technology George Emil Palade of Targu Mures, 540142 Targu Mures, Romania

* Correspondence: nandree96@yahoo.com (A.G.N.); gabrielabuicu@yahoo.com (E.G.S.)

Abstract: Inflammatory bowel disease (IBD), which includes Crohn's disease, ulcerative colitis, and unspecified inflammatory bowel disease, is a chronic, unpredictable and immune-mediated condition of the gastrointestinal tract. In pediatric populations, the diagnosis of a chronic and debilitating pathology significantly reduces quality of life. Children diagnosed with IBD may cope with physical symptoms such as abdominal pain or fatigue, but mental and emotional well-being are also important for preventing and reducing the risk of developing psychiatric conditions. Short stature, growth delay and delayed puberty can contribute to poor body image and low self-esteem. Furthermore, treatment per se can alter psycho-social functioning due to the side effects of medication and surgical procedures such as colostomy. It is essential to acknowledge and treat early signs and symptoms of psychiatric distress in order to prevent the development of serious psychiatric disorders in adult life. The literature underlines the importance of incorporating psychological and mental health services as part of the management of inflammatory bowel disease. Diagnosing mental health problems in pediatric patients with IBD can improve their adherence to treatment and pathology course and, consequently, reduce long-term morbidity and mortality.

Keywords: pediatric inflammatory bowel disease; psychiatric comorbidities; gut–brain axis



Citation: Sălcudean, A.; Nan, A.G.; Bodo, C.R.; Cosma, M.C.; Strete, E.G.; Lica, M.M. Association between Childhood Onset Inflammatory Bowel Disease and Psychiatric Comorbidities in Adulthood. *Diagnostics* **2023**, *13*, 1868. <https://doi.org/10.3390/diagnostics13111868>

Academic Editor: Cristina Oana Marginean

Received: 14 December 2022

Revised: 17 May 2023

Accepted: 24 May 2023

Published: 26 May 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Inflammatory bowel disease (IBD) is a group of chronic inflammatory conditions of the gastrointestinal system with a remitting–relapsing evolutive character. Crohn's disease (CD), ulcerative colitis (UC) and unspecified IBD are subtypes described in the literature [1]. Patients frequently experience symptoms such as abdominal pain, diarrhea, weight loss, and delayed growth or fatigue [2,3]. The presenting symptoms of pediatric IBD are summarized in Table 1.

Table 1. Frequent presenting symptoms in pediatric IBD [4].

General	Gastrointestinal Tract
Weight loss	Abdominal pain
Fever	Diarrhea
Anorexia	Rectal bleeding
Delayed growth	Nausea/vomiting
Lethargy/fatigue	Constipation
	Perianal disease (CD)
	Mouth ulcers

Inflammatory bowel disease is often associated with extraintestinal manifestations (EIM) and complications (EIC) [5]. Reportedly, EIM occur in approximately 5–50% of patients [5]. The organs most commonly affected are joints, skin, ocular system and hepatobiliary tract, although nearly every system may be involved [6]. Table 2 summarizes the extraintestinal manifestations and complications (EIM and EIC) of IBD.

Table 2. Extraintestinal manifestations (EIM) and complications (EIC) of IBD.

System	Manifestation/Complication
Generalized	Fever [7], weight loss [8], fatigue [7,9], nausea/vomiting/appetite changing [7]
Ocular	Uveitis/episcleritis/iritis/conjunctivitis [6,10]
Oral	Cheilitis/stomatitis/oral ulcerations [6,11]
Pulmonary	Pulmonary vasculitis/fibrosing alveolitis [12,13]
Vascular	Vasculitis/thrombosis [14,15]
Hepatobiliary	Primary sclerosing cholangitis/fatty liver disease/granulomatous hepatitis/autoimmune liver disease/cholestasis/gallstone formation [6,16]
Pancreatic	Pancreatitis (acute, chronic, autoimmune) [17]
Renal/Urinary	Nephrolithiasis [18]/tubulointerstitial nephritis [19]/glomerulonephritis [20]/amyloidosis [21]
Hematologic	Iron deficiency/chronic anemia/thrombocytosis/vitamin B12 deficiency/autoimmune hemolytic anemia [6,22]
Endocrine	Decreased growth velocity/delayed sexual maturation [23,24]
Integumentary	Erythema nodosum/pyoderma gangrenosum/perianal disease/CD [6,25]
Musculoskeletal Neuropsychiatric	Osteopenia and osteoporosis/arthritis/arthralgias/ankylosing spondylitis/sacroiliitis [23,26] Venous and arterial thrombotic and thromboembolic events/demyelinating diseases/peripheral neuropathies/white matter lesion/psychiatric disorders [27]

The burden of living with various and multisystemic symptoms, and the need for implementing treatment has piqued considerable interest in the mental health management of patients with IBD [28].

The incidence of inflammatory bowel disease (IBD) appears to be more common in northern countries as well as in industrialized areas [29], and studies have shown that the risk for serious mental illness is generally higher in cities compared to rural areas [30]. Approximately 25% of patients diagnosed with IBD are younger than 18 years old. Although pediatric incidence is currently lower than that in adults, it continues to increase, and there is evidence that the illness can be chronic and has a very aggressive evolution in this particular group of patients [1,31,32].

2. Psychological Implications in Inflammatory Bowel Disease

2.1. *Inflammatory Bowel Disease and Its Psychological Implications in Childhood and Young Adulthood*

The pediatric manifestation of inflammatory bowel disease cannot be separated from its psychosocial context. Children and adolescents frequently feel embarrassed and ashamed by fecal incontinence and frequent bathroom visits and often experience social anxiety due to school absences, nutritional strategies such as exclusion diets and distorted body image perception related to short stature or other physical effects of gastrointestinal diseases [33,34]. Additional factors such as age, social support network, primarily represented by the family and coping mechanisms to stress may also influence how adolescents manage and react to their somatic burden [35]. Fatigue is a common symptom reported by children affected by IBD [36] and it refers to a subjectively overwhelming sense of tiredness associated with lack of energy and exhaustion that decreases the capacity for physical and mental activity, decreasing quality of life in similar ways as rheumatologic disease and cancer [37,38]. Fatigue, exhaustion, diminished physical activity and trouble sleeping are more common in children and adolescents with IBD than in their healthy counterparts. Fatigue is likely to be a multifactorial phenomenon and includes biological factors (such as disease activity), psycho-behavioral factors (such as anxiety, depression and family support) disorder [39]. The above-described factors can contribute to significant psychological and functional factors (such as decreased functional capacity) [37,38]. Moreover, fatigue represents a core symptom in major depressive burden that influences disease outcomes and patient's psychological development [40].

Moreover, inflammatory bowel disease is increasingly being recognized as a complex multifactorial and multisystemic disorder [6]. Alarming high rates of depression within the adolescent IBD population have been observed in the largest population-based study, which aimed to evaluate the burden of psychiatric disorders in children and young adults with IBD in USA, comprising a total of 11,316,450 patients aged between 5 and 24 years, including 58,020 patients with a diagnosis of IBD. The prevalence of psychiatric disorders was found to be 21.6% among IBD, and mainly comprised depression and anxiety disorders. The study's results also indicate that IBD is five times more likely to be associated with psychiatric disorders than controls ($p < 0.001$) [41]. Furthermore, studies on pediatric and adult populations show a significant relationship between depression and anxiety with IBD disease activity and evolution [42–44]. In 2018, Van den Brink et al. conducted a randomized controlled trial, concluding that active disease was a significant risk factor for depressive symptoms (OR 4.6, $p < 0.001$). Other significant risk factors for anxiety and/or depression included female gender (OR 1.7), active disease (OR 1.9), and a shorter disease duration (OR 1.4) (all $p < 0.025$) [43]. Furthermore, a meta-analytic review comprising a total of 1167 young people with IBD (M age = 14.33, 50% female) concluded that they had higher rates of depressive disorders and internalizing disorders than young people with other chronic conditions [45]. Extensive research has explored the idea that mental health comorbidities are only a direct result of the global burden of living with a chronic disease or complex mechanism involved in gut–brain interactions. Recent studies indicate that the relationship between IBD and mental illness can be bidirectional, evoking the systemic inflammation that damages the body's immune and nervous systems and is a possible mechanism for both IBD and mental illness, as well as complex gut–brain interactions [46–49]. Moreover, another management impairment is that patients with IBD and co-morbid depression and/or anxiety may be less likely to adhere to medical care procedures and therapeutic schemes, resulting in unnecessary escalation in therapy and complications [50–52]. The importance of family support and the coordination of the medical treatment are factors of pediatric IBD management that can impact psychological outcomes for children affected by the disease [53]. Younger and middle-aged adolescents benefitted from family support in the context of IBD care management according to Feldman et al.'s (2020) analysis conducted on 76 young IBD patients aged between 11 and 18 [51]. Dealing with a chronic illness and a lifelong management can be overwhelming

for children [54]. As described in other chronic disease such as diabetes, poor treatment adherence can cause a high prevalence of psychiatric comorbidities [55]. Lifestyle changes sometimes occur unexpectedly due to disease exacerbation, impacting the lives of both patient and parents, resulting in disruptions to family life. According to a study comprising 87 patients and their parents, a worse disease course was directly associated with the increased distress of parents and indirectly with the lower health-related quality of life (HRQOL) of pediatric patients with IBD, emphasizing that parental distress should be considered in the management of pediatric IBD to improve HRQOL of children [56,57].

Anxiety symptoms may also be related to arising concerns about different lifestyles compared to other children and related to the unknown progression of the illness (relapse or complications of disease requiring surgical procedures or colostomy that can impact one's body-image perception and self-esteem) [34,58]. Social impairments may be caused by educational deficiencies due to school absences [59,60], as well as low self-esteem due to delayed development or a lack of satisfaction with one's physical appearance [61]. It is also important to acknowledge and prevent any educational impairments of children with IBD in order to prevent any delays in educational acquisitions. The financial burden of a chronic illness as well as familial sacrifices, repeated hospitalizations, and family issues are problems that a child with IBD may face [62].

Assessing the adaptation of pediatric patients to disease is an important component of long-term management of children with IBD. Existing models of assessment tools focus on evaluating a patient's social support network, coping mechanisms and skills, daily activities, and body image perception [56,57].

2.2. Critic Period: Transition from Pediatric to Adult Inflammatory Bowel Disease Care

While the pediatric management of chronic illnesses includes the benefit provided by the patients' family support, the transition from children to adult life mandates the development of abilities of self-management and self-care. This transition can be facilitated by gradually increasing the patient's responsibility and participation in their care plan. Older adolescents should be taught to recognize the warning signs of an emergency and be able to appropriately describe the manifestations and seek immediate treatment, as well as being familiar with administered medication. It is well documented that any discontinuity in patients with IBD care during the transition from a pediatric to adult patient can result in severe adverse outcomes, unfavorable evolution and higher medical costs [53]. Because most patients with pediatric-onset inflammatory bowel disease progress into adulthood, the chances of disease's long- and short-term complications increase, and burdens of IBD are also increased by psychosocial factors including poor coping ability and other obstacles regarding medical management, as described above. The economic burden and financial impact of a chronic illness must be taken into account in patients experiencing chronic and debilitating symptoms, especially regarding the current evidence for an impaired quality of working life in IBD patients [63]. Regarding work impairments, concentration problems (72%), low working pace (78%) and delayed work productivity (50%) were the most prevalent IBD-related work difficulties described in a questionnaire-based study including 202 IBD patients [64].

It is ideal for the transition from pediatric to adult care to happen when young adults already have a basic understanding of IBD, as well as its therapeutic schemes, prognosis and evolution in both the presence and absence of specific treatments [65,66]. Somatic disease course is beneficial for young adults who have stable mental health, sufficient self-efficacy and are willing to communicate regarding self-care behaviors, developing a beneficial patient–healthcare worker relationship [66,67]. On the other hand, it is widely known that self-management skills may be undermined by the onset of mental illnesses or other psychosocial problems; therefore, it is critical to efficiently diagnose and treat any mental-health-related disturbances.

Findings from a pilot study conducted in the United States of America aimed to understand disease transitions from a broader psychosocial perspective. The results show

that transition barriers include disease uncertainty and lack of control, psychological distress, and disruptions to daily life [33]. Facilitators such as mental health support, adequate social support and adequate communication ease the transition process for young patients. Furthermore, the study highlights certain particular and adaptable interventions for facilitating the transition to adulthood IBD care and management, as presented in Table 3 [33,68–70].

Table 3. Interventions considered to facilitate IBD care transition [33].

Adaptable Intervention	Elements/Examples
Develop a disease narrative	What is IBD and what symptoms are most prominent for you day-to-day? What are some of the challenges that you might experience related to having IBD (e.g., managing medications, medical procedures, dietary or activity restrictions)? In what ways have you grown through the challenges of living with IBD?
Practice gratitude	Write a gratitude letter Keep a gratitude journal
Pay it forward	Engagement with the IBD community Voluntary Mentorship
Set SMART Goals	Specific Measurable Achievable Relevant Time-sensitive
Master the gut–brain axis	Optimizing education about the complex interactions of the gut and brain axis Understanding relationship stress symptoms Useful questions: What do you notice about how your stress levels influence your IBD symptoms? Conversely, when you begin to experience the onset of IBD symptoms, how does that impact your mental state?

Although we present several interventions/facilitators, additional research is needed to evaluate the impact of incorporating these exercises into psychosocial programs and to discover further targeted interventions designed to facilitate the transition process.

Finally, these interventions can be introduced to patients at any age and in any order following the opinion of a healthcare professional regarding the most appropriate treatment for the patient and their particularities. However, if not previously initiated, the pediatric-to-adult transition may benefit from the inclusion of these interventions in care management.

The above-mentioned interventions are recommendations that can be implemented during the pediatric IBD care management or as part of transitioning process. The interventions are based on positive psychology and cognitive-behavioral principles, which may be associated with improved disease outcomes across the spectrum of digestive disorders [71].

These facilitating interventions can be introduced to patients at any age and include the following recommendations:

- Develop a disease narrative to develop ways to talk about IBD with those who are not familiar with the disease. Before transitioning to adult care, pediatric patients may benefit from establishing their own disease narrative. By discussing how the disease has affected the patient's life experiences in a positive way can encourage patients to adopt an optimistic point of view, be self-efficient, and advocate for themselves. This method of communication strengthens mechanisms of growth and learning abilities and was previously associated with happiness, gratefulness, as well as reduced stress and depressive symptoms [72].

- Practicing gratitude has the benefit of enhancing support and strengthening existing connections and social support networks. Examples of gratitude activities include writing letters (in which the patient expresses their gratitude to the persons that helped them during difficult times) and writing a gratitude journal (logging disease symptoms and subsequent emotions that can be easily accessed to help patients focus on the positive aspects of their lives) [33,73].
- Paying it forward means to engage in IBD community activities such as volunteering and mentorship for the newly diagnosed patients. These interventions can boost self-efficacy and are associated with increased satisfaction, well-being and happiness [74].
- Setting SMART goals is a means to divide up large and sometimes difficult goals into smaller and more achievable targets. Setting SMART goals for IBD management can allow adolescent patients and their caregivers to prioritize the goals of interest, focusing on optimizing their chances of successfully completing the tasks, consequently building efficacy that prepares patients to reach the disease management independency.

SMART is an acronym that highlights the key features of the goal:

- Specific: what, where, and when will we work toward on this goal?
- Measurable: how can we evaluate if we have achieved the goal or not?
- Achievable: is this goal within the realm of possibility?
- Relevant to larger goals: does this goal fit into my value system?
- Time-sensitive: at what point will we check in on progress to determine whether we have reached the goal? [75]
- Mastering the gut–brain axis means to optimize education about the complex interactions of the gut–brain axis that may help pediatric patients to better manage their disease. Helping patients differentiate between their symptoms can help reduce concerns for those who may feel that stress-induced symptoms are not important. It is therefore mandatory for doctors to identify certain concerning symptoms and establish multidisciplinary approaches with qualified mental health professionals (psychologists and psychiatrists) [33,76].

2.3. Anatomopathology and Reported Pathogenesis of Psychiatric Implications in Patients with Inflammatory Bowel Disease

The complexity of the gut–brain axis has sparked significant interest from researchers over the last twenty years [49,77,78]. The gut–brain axis is a complex bidirectional communication system driven by neural, hormonal, metabolic, immunological, and microbial signals [77,78]. Signaling events from the gut can modulate brain function, and recent evidence suggests that the gut–brain axis may play a pivotal role in linking gastrointestinal and neuropsychiatric pathologies [78,79]. In a review article, RK Masanetz et al. explored a series of cascade events along the gut–immune–brain axis, initiated by the evasion of chronic intestinal inflammation, that pass through the epithelial–vascular barrier in the gut and cause systemic inflammation [79]. Moreover, the malfunctioning of the gut–brain axis described in IBD patients includes structural and functional abnormalities of the enteric nervous system (ENS) and induced abnormal, innate, and adaptive immunological responses, affecting intestinal barrier integrity and leading to systemic fallout [80]. It has been postulated that neuroinflammation-induced depression in IBD involves peripheral inflammatory mediators originating from the inflammation in the gastrointestinal system, penetrating the blood–brain barrier and activating the resident macrophage-like microglial cells within the central nervous system [46,81,82].

It has been reported that neuroinflammation can induce the dysregulation of the hypothalamus–pituitary–adrenal (HPA) axis [83] and decrease serotonin levels [84], as well as altering the hippocampus [85], mechanisms involved in major depressive disorder (MDD) [81]. In a previous study, low serum serotonin levels were correlated with depressive symptoms [86] and in a small study, plasmatic serotonin level was used as a screening

marker for anxiety and depression in patients with type 2 diabetes [87]. Further studies are essential for evaluating the use of serum serotonin as a predictor of depression.

Bonaz BL (2013) suggested a dysfunction of brain–gut interactions in the pathogenesis of IBD, evidenced by the dysfunctionality of the autonomic nervous system and abnormal functioning of the hypothalamic–pituitary–adrenal axis. Their study is supported by [77], which found similar results for the cholinergic anti-inflammatory pathway [88]. The harmful effect of stress, abnormal association of the prefrontal cortex–amygdala, and an abnormal microbiota–brain relationship were found in pro-inflammatory models [83,88].

In Neurogastroenterology and Motility, Agostini et al. (2013) evaluated patients with Crohn's disease for brain volumetric alterations, and the results indicate decreased gray matter volumes in the dorsolateral prefrontal cortex and anterior midcingulate cortex. Illness time evolution was negatively correlated with volumetric measures in the subgenual anterior cingulate cortex, posterior midcingulate cortex, ventral posterior cingulate, and parahippocampal cortex [89]. The anterior midcingulate cortex was responsible for feedback-mediated decision making [90]. The gray matter volume in the subgenual anterior cingulate cortex was found to be abnormally reduced in subjects with major depressive disorder and bipolar disorder [91,92]. The ventral posterior cingulate cortex plays a role in self-monitoring the personal relevance of somatosensory stimuli. It is also involved in spatial processing, actions in space, and some types of memory pathways [93] that may be interrupted by posterior cingulate cortex atrophy, as discovered in small studies of Crohn's disease [89,94]. Moreover, a systematic multi-database study comparing adult IBD patients versus healthy controls ($n = 687$) concluded that IBD patients had significant deficits in attention, executive function, and working memory compared with healthy controls, suggesting that cognitive impairment is a potential extraintestinal manifestation of IBD [95]. Another small comparative study on a pediatric population found that patients with IBD and cystic fibrosis performed more poorly than healthy controls in attention and memory tests [96].

Moreover, white matter alterations have also been observed in IBD patients compared to controls in a small number of studies on nervous system imaging in patients with IBD. The lesions were clinically asymptomatic and potentially associated with IBD, and whether these structural changes represent a unique extraintestinal manifestation of the disease remains unclear and further studies must be conducted [97]. In contrast, a study with a relatively small sample size did not find an increased rate of white matter lesions among patients with IBD when compared to healthy controls [98]. Conflicting data and small studies regarding white matter lesions mandate further studies.

Inflammatory bowel disease has been associated with a higher risk of cerebrovascular accidents [99] according to a study including 261,890 IBD patients compared to non-IBD patients (6.24% vs. 0.48%, $p < 0.0001$) [100]. The hypercoagulability [14] state present in IBD could be a mechanism by which the presence of IBD might lead to the development of cerebrovascular accidents.

2.4. Mental Disorders Associated with Inflammatory Bowel Disease

In patients with IBD, several studies have described an increased frequency of various mental disorders, ranging from mild depression to severe forms of schizophrenia and serious dementia, but the prevalence of mental disorders depends on the study, as described below.

Upon examining the literature, depression and anxiety disorders were the most studied mental health disorders, both in pediatric and adult IBD patients [41,101,102].

IBD patients often suffer from anxiety and depression that may influence the course of disease via the complexity of the gut–brain axis [101]. In a systematic review, Mickoka et al. (2016) demonstrated that the prevalence of anxiety and depression is higher in patients with IBD and even higher in the active phase of the disease [101]. A review and meta-analysis of 60,114 adult and pediatric IBD patients identified high prevalence of: mood disorders, 10%; anxiety disorders, 12%; substance misuse, 3%; psychotic disorders, 2%; behavioral

disorders, 1%; personality disorders, 3%; developmental disorders, 1%; and behavioral and emotional disorders with onset usually during childhood, 1% [102].

Thavamani et al. conducted a retrospective case–control analysis, including 58,020 IBD pediatric patients, of which 12,540 were diagnosed with psychiatric disorders. Depression, anxiety and adjustment disorder contributed to about 95% of all psychiatric disorders. Among the screened psychiatric disorders, IBD patients had an increased risk of associated anxiety, depression, panic disorder, phobias and dysthymias [41]. The study results are presented in Table 4.

Table 4. Association between psychiatric disorders and inflammatory bowel disease in pediatric population and young adults (<24 years) (adapted following Thavamani et al.) [41].

Mental Health Disorder	Odds Ratio (OR)	Lower CI–Upper CI	<i>p</i> -Value
Bipolar disorder	3.5	3.3–3.73	<0.001
Depression	3.94	3.82–4.06	<0.001
Anxiety disorder	4.05	3.96–4.16	<0.001
Any mental health disorder	3.83	3.75–3.91	<0.001

Comparatively, Bernstein et al. conducted a retrospective matched-control study analyzing the incidence and prevalence of psychiatric disorders in an adult IBD cohort compared with a matched cohort without IBD [103]. The results are presented in Table 5.

Table 5. Association between psychiatric disorders and inflammatory bowel disease in young adult (18–24 years) and adult populations (>24 years) (adapted following [103]).

Mental Health Disorder	IRR Incidence Rate Ratio in IBD Patients	IRR in Match Cohort	<i>p</i> Value
Depression	1.58 (>)	1.0	<i>p</i> < 0.05
Anxiety disorder	1.39 (>)	1.0	<i>p</i> < 0.05
Bipolar disorder	1.82 (>)	1.0	<i>p</i> < 0.05
Schizophrenia	1.64 (>)	1.0	<i>p</i> > 0.05

Various researchers studied the risk factors of depression among patients with IBD and concluded that age, severe disease, flare ups, disability, unemployment, socioeconomic impairment [104] and coronavirus disease 2019 isolation due to extensive lockdown measures are factors responsible for developing depressive symptoms [105]. Various studies highlight the increased risk of suicide among IBD patients [106–108].

There is conflicting research data regarding the association between bipolar disorder and inflammatory bowel disease. A population-based, cross-sectional study from Taiwan demonstrated that patients with IBD were more likely to have bipolar disorder. Moreover, a national cohort study conducted in Denmark presented a higher risk of bipolar disorder only in patients with CD [109,110]. Thavamani et al. observed a high odds ratio (OR) of bipolar disorder in an IBD pediatric population [41]. In 2022, Wang et al. found a significant, positive association for genetically predicted bipolar disorder with the risk for IBD and ulcerative colitis (per log/odds ratio increase; odds ratios: 1.18 and 1.19, respectively) [111].

Regarding comorbid IBD–schizophrenia, studies show inconsistent results. While a population-based cohort study conducted in Taiwan (2020) demonstrated a significant association between schizophrenia and subsequent IBD development (1.14% vs. 0.25% in non-IBD population), other studies failed to demonstrate any association between somatic and mental illnesses [112,113]. In pediatric populations, rare and isolated cases of medication-induced psychosis are described in the literature [114,115].

Recent evidence suggests there is a possible association between IBD and eating disorders, although the exact mechanisms involved in its ethio-pathogenesis are not fully understood. This association may lead to worse prognosis [108,116,117].

Table 6 presents the association between childhood-onset inflammatory bowel disease and mental health disorders in adulthood as well as the specific adaptation hazard ratios as found by Butwicka et al. (2019) [108].

Table 6. Association between childhood-onset IBD and psychiatric comorbidities [108].

Psychiatric Pathology in Patients with Childhood-Onset Inflammatory Bowel Disease						
Psychiatric Pathology	Ulcerative Colitis		Crohn's Disease		IBD—Unclassified	
	HR (85% CI)	<i>p</i> Value	HR (85% CI)	<i>p</i> Value	HR (85% CI)	<i>p</i> Value
Psychotic disorders	0.9 (0.5–1.5)	0.58	1.3 (0.8–2.2)	0.27	0.8 (0.2–3.1)	0.7
Mood disorder	1.4 (1.3–1.7)	<0.001	1.6 (1.4–1.9)	<0.001	1.8 (1.3–2.4)	<0.001
Anxiety disorders	1.6 (1.4–1.8)	<0.001	2.2 (1.9–2.4)	<0.001	2.4 (1.9–3.0)	<0.001
Eating disorders	1.3 (0.9–1.8)	0.13	1.9 (1.4–2.6)	<0.001	2.4 (1.3–4.3)	0.005
Substance misuse	1.1 (0.9–1.3)	0.33	1.2 (0.9–1.4)	0.16	0.7 (0.4–1.1)	0.12
Personality disorders	1.4 (1.0–2.0)	0.03	1.2 (0.8–1.8)	0.44	2.0 (1.0–3.9)	0.04
Behavioral disorders	0.8 (0.3–1.9)	0.64	2.0 (1.0–3.9)	<0.05	1.4 (0.3–5.8)	0.62
ADHD	1.2 (1.0–1.5)	0.07	1.2 (0.9–1.5)	0.13	1.1 (0.6–1.7)	0.8
Autism spectrum disorders	1.5 (1.1–2.1)	0.01	1.2 (0.8–1.7)	0.42	1.6 (0.8–3.3)	0.19
Intellectual disability	1.1 (0.7–1.9)	0.62	0.9 (0.4–1.7)	0.68	2.7 (1.2–5.7)	0.01
All psychiatric disorders	1.4 (1.3–1.5)	<0.001	1.7 (1.6–1.9)	<0.001	1.8 (1.5–2.1)	<0.001
Suicide attempts	1.2 (0.9–1.6)	0.23	1.5 (1.1–2.0)	0.01	2.3 (1.4–3.8)	0.001

Abbreviations: HR—hazard ratio, IBD—inflammatory bowel disease.

Moreover, suicide represents a serious global public health burden. According to the WHO (World Health Organization), approximately 703,000 people per year die from suicide worldwide [118]. In 2019, suicide accounted for more than 1 out of 100 deaths, and 58% of suicides occurred before age 50. Mental disorders are the leading cause of disability worldwide, accounting for one in six cases of disability [119]. Patients diagnosed with severe mental health conditions die on average 10–20 years earlier than the general population. Sexual molesting and bullying are major causes of depression in children, and bullying should not be overlooked in pediatric IBD patients, especially in those who lack confidence in their physical appearance [119].

The most severe outcome in patients with depression is suicide, but the risk of suicide in patients with IBD is not entirely clear. A systematic review based on 28 studies concluded that patients with inflammatory bowel disease were associated with an increased risk of suicide attempts (relative risk = 1.39; 95% CI, 1.08–1.79) and deaths from suicide (relative risk = 1.25; 95% CI, 1.09–1.43) compared to controls. The review also concluded that Crohn's disease subtypes, female patients, childhood-onset IBD, young-adult IBD, and short-duration IBD characteristics are factors that carry a high risk of suicide [106]. Another case–control study regarding the Danish population highlights the necessity to correctly assess the risk of suicide among IBD patients. The results indicate increased rates of suicide among participants with CD (odds ratio = 1.6, 95%) and UC (OR = 1.9, 95%) [120]. Butwicka et al. observed an increased hazard ratio (HR = 1.2, respectively 1.5) in UC and childhood-onset CD [108].

Regarding these findings, healthcare providers should consider a multidisciplinary approach that includes medical and psychological factors. Psychological factors should always be considered via assessments of depressive symptomology and the co-occurrence of suicide risk, especially if patients with IBD present co-occurring factors, such as active disease phase or high pain levels, that increase the risk of suicide [59]. The identification and treatment of mental health conditions such as depression in IBD populations is essential for reducing the high number of patients at risk of suicide [121]. Childhood traumas must also be assessed, as certain traumatic events may increase suicide risk [122].

3. Conclusions

To our knowledge, childhood-onset inflammatory bowel disease has an impact on more than just the gastrointestinal tract; patients often have psychological comorbidities and mental health implications further in adult life. Although the pathogenetic mechanisms between inflammatory bowel disease and mental illnesses are not fully elucidated, genetic factors and the gut–brain interaction seem to contribute to the increased prevalence of mental disorders in patients with IBD, and further studies must be established in order to describe and elucidate the complex mechanisms. Childhood-onset inflammatory bowel disease tends to have a more severe evolutive course than IBD diagnosed in adulthood, and mental health burden adds to the overall low quality of life rates described in this particular group of patients. Psychiatric comorbidities are independent predictors of the severity of IBD symptoms, not only negatively impacting a patient's quality of life, but also increasing healthcare utilization and economic burden. The importance of family support and the coordination of the medical treatment is a particularity that can impact psychological outcomes for children affected by inflammatory bowel disease. Addressing mental health problems in pediatric patients with IBD can improve their medication adherence and somatic disease course, reducing overall morbidity and mortality. Specific measurable variables such as serum serotonin levels may become useful tools in assessing a patients' risk of developing psychiatric comorbidities such as depression, but further larger research studies are required.

Understanding the need to implement various transition mechanisms of psychological support from childhood to adulthood care in patients with IBD is important for both healthcare providers and insurance payers, as it has a direct impact on medical care and disease outcomes. It is ideal for the transition from child to adult care to happen when young adults already have a good general understanding of their disease. Social and educational impairments in pediatric patients require special attention regarding the management of inflammatory bowel disease patients because adaptation difficulties can underlie the development of serious mental health problems in adult life and decrease the global functionality.

Somatic disease courses may benefit patients who are stable in terms of their mental health and have sufficient self-efficacy and willingness to communicate regarding self-care behaviors.

The increased frequency of psychiatric comorbidities in childhood-onset inflammatory bowel disease, as described in the literature, especially mood and anxiety disorders, demonstrates that early interventions can prevent and attenuate the development of serious psychiatric pathologies; however, further studies and investigations are mandatory for developing the best approaches and multidisciplinary protocols to manage mental health implications in pediatric inflammatory bowel disease. We believe that further prospective follow-up studies on the prevalence of psychiatric disorders in childhood-onset IBD populations would be greatly valuable and of considerable interest to researchers.

Author Contributions: Conceptualization, A.S., E.G.S. and M.M.L.; methodology, A.S., E.G.S., A.G.N. and M.C.C.; validation, A.S. and E.G.S.; investigation, A.S., A.G.N., M.C.C. and C.R.B.; writing—original draft preparation, A.S. and A.G.N.; writing—review and editing, A.S., A.G.N., C.R.B., E.G.S., M.C.C. and M.M.L.; supervision, A.S. All authors have read and agreed to the published version of the manuscript.

Funding: This study was funded by George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Targu Mures, Research Grant Number 164/25/10.01.2023.

Institutional Review Board Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

CD	Crohn's disease
CI	Confidence interval
EIM	Extraintestinal manifestations
EIC	Extraintestinal complications
HPA	Hypothalamus–pituitary–adrenal axis
HRQOL	Health-related quality of life
IBD	Inflammatory bowel disease
MDD	Major depressive disorder
OR	Odds ratio
IRR	Incidence rate ratio
UC	Ulcerative colitis
WHO	World Health Organization

References

- Conrad, M.A.; Rosh, J.R. Pediatric Inflammatory Bowel Disease. *Pediatr. Clin. N. Am.* **2017**, *64*, 577–591. [\[CrossRef\]](#) [\[PubMed\]](#)
- Diefenbach, K.A.; Breuer, C.K. Pediatric inflammatory bowel disease. *World J. Gastroenterol.* **2006**, *12*, 3204–3212. [\[CrossRef\]](#) [\[PubMed\]](#)
- Murch, S.H.; Baldassano, R.; Buller, H.; Chin, S.; Griffiths, A.M.; Hildebrand, H.; Jasinsky, C.; Kong, T.; Moore, D.; Orsi, M. Inflammatory Bowel Disease: Working Group Report of the Second World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition. *J. Pediatr. Gastroenterol. Nutr.* **2004**, *39* (Suppl. S2), S647–S654. [\[CrossRef\]](#)
- Rosen, M.J.; Dhawan, A.; Saeed, S.A. Inflammatory Bowel Disease in Children and Adolescents. *JAMA Pediatr.* **2015**, *169*, 1053–1060. [\[CrossRef\]](#)
- Malik, T.F.; Aurelio, D.M. Extraintestinal Manifestations of Inflammatory Bowel Disease. In *StatPearls*; StatPearls Publishing: Tampa, FL, USA, 2022.
- Aloi, M.; Cucchiara, S. Extradigestive manifestations of IBD in pediatrics. *Eur. Rev. Med. Pharmacol. Sci.* **2009**, *13* (Suppl. S1), 23–32.
- Singh, S.; Blanchard, A.; Walker, J.R.; Graff, L.A.; Miller, N.; Bernstein, C.N. Common Symptoms and Stressors Among Individuals with Inflammatory Bowel Diseases. *Clin. Gastroenterol. Hepatol.* **2011**, *9*, 769–775. [\[CrossRef\]](#) [\[PubMed\]](#)
- Moeni, V.; Day, A.S. Impact of Inflammatory Bowel Disease upon Growth in Children and Adolescents. *ISRN Pediatr.* **2011**, *2011*, 365712. [\[CrossRef\]](#) [\[PubMed\]](#)
- Jelsness-Jørgensen, L.-P.; Bernklev, T.; Henriksen, M.; Torp, R.; Moum, B.A. Chronic fatigue is more prevalent in patients with inflammatory bowel disease than in healthy controls. *Inflamm. Bowel Dis.* **2011**, *17*, 1564–1572. [\[CrossRef\]](#)
- Troncoso, L.L.; Biancardi, A.L.; de Moraes, H.V., Jr.; Zaltman, C. Ophthalmic manifestations in patients with inflammatory bowel disease: A review. *World J. Gastroenterol.* **2017**, *23*, 5836–5848. [\[CrossRef\]](#)
- Klichowska-Palotka, M.; Komsta, A.; Pac-Kozuchowska, E. The condition of the oral cavity at the time of diagnosis of inflammatory bowel disease in pediatric patients. *Sci. Rep.* **2021**, *11*, 21898. [\[CrossRef\]](#)
- Ji, X.-Q.; Wang, L.-X.; Lu, D.-G. Pulmonary manifestations of inflammatory bowel disease. *World J. Gastroenterol.* **2014**, *20*, 13501–13511. [\[CrossRef\]](#)
- Olpin, J.D.; Sjöberg, B.P.; Stilwill, S.E.; Jensen, L.E.; Rezvani, M.; Shaaban, A.M. Beyond the Bowel: Extraintestinal Manifestations of Inflammatory Bowel Disease. *Radiographics* **2017**, *37*, 1135–1160. [\[CrossRef\]](#) [\[PubMed\]](#)
- Zesos, P.; Kouklakis, G.; Saibil, F. Inflammatory bowel disease and thromboembolism. *World J. Gastroenterol.* **2014**, *20*, 13863–13878. [\[CrossRef\]](#)
- Arvanitakis, K.D.; Arvanitaki, A.D.; Karkos, C.D.; Zintzaras, E.A.; Germanidis, G.S. The risk of venous thromboembolic events in patients with inflammatory bowel disease: A systematic review and meta-analysis. *Ann. Gastroenterol.* **2021**, *34*, 680–690. [\[CrossRef\]](#) [\[PubMed\]](#)
- Yarur, A.J.; Czul, F.; Levy, C. Hepatobiliary manifestations of inflammatory bowel disease. *Inflamm. Bowel Dis.* **2014**, *20*, 1655–1667. [\[CrossRef\]](#) [\[PubMed\]](#)
- Fousekis, F.S.; Theopistos, V.I.; Katsanos, K.H.; Christodoulou, D.K. Pancreatic Involvement in Inflammatory Bowel Disease: A Review. *J. Clin. Med. Res.* **2018**, *10*, 743–751. [\[CrossRef\]](#) [\[PubMed\]](#)
- Ganji-Arjenaki, M.; Nasri, H.; Rafieian-Kopaei, M. Nephrolithiasis as a common urinary system manifestation of inflammatory bowel diseases: A clinical review and meta-analysis. *J. Nephrol. Pathol.* **2017**, *6*, 264–269. [\[CrossRef\]](#)
- Tokuyama, H.; Wakino, S.; Konishi, K.; Hashiguchi, A.; Hayashi, K.; Itoh, H. Acute interstitial nephritis associated with ulcerative colitis. *Clin. Exp. Nephrol.* **2010**, *14*, 483–486. [\[CrossRef\]](#)
- Ambruzs, J.M.; Walker, P.D.; Larsen, C.P. The Histopathologic Spectrum of Kidney Biopsies in Patients with Inflammatory Bowel Disease. *Clin. J. Am. Soc. Nephrol.* **2014**, *9*, 265–270. [\[CrossRef\]](#)
- Elaziz, M.M.A.; Fayed, A. Patterns of renal involvement in a cohort of patients with inflammatory bowel disease in Egypt. *Acta Gastro Enterol. Belg.* **2018**, *81*, 381–385.

22. Shizuma, T. Coexistence of Crohn's Disease and Autoimmune Hemolytic Anemia. *Austin. J. Gastroenterol.* **2015**, *2*, 1043.
23. Jin, H.-Y.; Lim, J.-S.; Lee, Y.; Choi, Y.; Oh, S.-H.; Kim, K.-M.; Yoo, H.-W.; Choi, J.-H. Growth, puberty, and bone health in children and adolescents with inflammatory bowel disease. *BMC Pediatr.* **2021**, *21*, 35. [\[CrossRef\]](#) [\[PubMed\]](#)
24. Amaro, F.; Chiarelli, F. Growth and Puberty in Children with Inflammatory Bowel Diseases. *Biomedicines* **2020**, *8*, 458. [\[CrossRef\]](#)
25. Stephan, R.V.; Schoepfer, A.; Scharl, M.; Lakatos, P.L.; Navarini, A.; Rogler, G. Extraintestinal Manifestations of Inflammatory Bowel Disease. *Inflamm. Bowel Dis.* **2015**, *21*, 1982–1992. [\[CrossRef\]](#)
26. Fornaciari, G.; Salvarani, C.; Beltrami, M.; Macchioni, P.L. Musculoskeletal manifestations in inflammatory bowel disease. *Can. J. Gastroenterol.* **2001**, *15*, 399–403. [\[CrossRef\]](#)
27. Plata-Bello, J.; Acosta-López, S. Neurological Manifestations of Inflammatory Bowel Disease. In *New Concepts in Inflammatory Bowel Disease*; Intechopen: London, UK, 2018. [\[CrossRef\]](#)
28. Umar, N.; Harvey, P.; King, D.; Chandan, J.S.; Nirantharakumar, K.; Adderley, N.; Haroon, S.; Trudgill, N. O33 The association between IBD and mental ill health: A retrospective primary care cohort study. *Gut* **2022**, *71*, A20–A21.
29. Cui, G.; Liu, H.; Xu, G.; Laugsand, J.-B.; Pang, Z. Exploring Links Between Industrialization, Urbanization, and Chinese Inflammatory Bowel Disease. *Front. Med.* **2021**, *8*, 757025. [\[CrossRef\]](#)
30. Gruebner, O.; Rapp, M.A.; Adli, M.; Kluge, U.; Galea, S.; Heinz, A. Cities and Mental Health. *Dtsch. Arztebl. Int.* **2017**, *114*, 121–127. [\[CrossRef\]](#)
31. Kuenzig, M.E.; Fung, S.G.; Marderfeld, L.; Mak, J.W.; Kaplan, G.G.; Ng, S.C.; Wilson, D.C.; Cameron, F.; Henderson, P.; Kotze, P.G.; et al. Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review. *Gastroenterology* **2022**, *162*, 1147–1159.e4. [\[CrossRef\]](#)
32. Mamula, P.; Markowitz, J.E.; Baldassano, R.N. Inflammatory bowel disease in early childhood and adolescence: Special considerations. *Gastroenterol. Clin. N. Am.* **2003**, *32*, 967–995. [\[CrossRef\]](#)
33. Mendiola Michelle, L.; Feingold Jordyn, H.; Kaye-Kauderer Halley, P.; Dubinsky Marla, C.; Gorbenko Ksenia, O.; Keefer Laurie, A. Transitions from pediatric to adult IBD care: Incorporating lessons from psychogastroenterology. *Front. Gastroenterol.* **2022**, *1*, 037421. [\[CrossRef\]](#)
34. Kum, D.J.; Bang, K.-S. Body image, self-esteem, and quality of life in children and adolescents with inflammatory bowel disease in a tertiary hospital in South Korea. *Child Health Nurs. Res.* **2021**, *27*, 181–189. [\[CrossRef\]](#)
35. Murray, C.D.R.; Flynn, J.; Ratcliffe, L.; Jacyna, M.R.; Kamm, M.A.; Emmanuel, A.V. Effect of acute physical and psychological stress on gut autonomic innervation in irritable bowel syndrome. *Gastroenterology* **2004**, *127*, 1695–1703. [\[CrossRef\]](#)
36. Van De Vijver, E.; Van Gils, A.; Beckers, L.; Van Driessche, Y.; Moes, N.D.; Van Rheeën, P.F. Fatigue in children and adolescents with inflammatory bowel disease. *World J. Gastroenterol.* **2019**, *25*, 632–643. [\[CrossRef\]](#)
37. van Langenberg, D.R.; Gibson, P.R. Systematic review: Fatigue in inflammatory bowel disease. *Aliment. Pharmacol. Ther.* **2010**, *32*, 131–143. [\[CrossRef\]](#) [\[PubMed\]](#)
38. Marcus, S.B.; Stroppe, J.A.; Neighbors, K.; Weissberg-Benchell, J.; Nelson, S.P.; Limbers, C.; Varni, J.W.; Alonso, E.M. Fatigue and Health-Related Quality of Life in Pediatric Inflammatory Bowel Disease. *Clin. Gastroenterol. Hepatol.* **2009**, *7*, 554–561. [\[CrossRef\]](#) [\[PubMed\]](#)
39. Ghanean, H.; Ceniti, A.K.; Kennedy, S.H. Fatigue in Patients with Major Depressive Disorder: Prevalence, Burden and Pharmacological Approaches to Management. *CNS Drugs* **2018**, *32*, 65–74. [\[CrossRef\]](#) [\[PubMed\]](#)
40. Mackner, L.M.; Greenley, R.N.; Szigethy, E.; Herzer, M.; Deer, K.; Hommel, K.A. Psychosocial issues in pediatric inflammatory bowel disease: Report of the north American society for pediatric gastroenterology, hepatology, and nutrition. *J. Pediatr. Gastroenterol. Nutr.* **2013**, *56*, 449–458. [\[CrossRef\]](#)
41. Thavamani, A.; Umapathi, K.K.; Khatana, J.; Gulati, R. Burden of Psychiatric Disorders among Pediatric and Young Adults with Inflammatory Bowel Disease: A Population-Based Analysis. *Pediatr. Gastroenterol. Hepatol. Nutr.* **2019**, *22*, 527–535. [\[CrossRef\]](#)
42. Brink, G.V.D.; Stapersma, L.; Vlug, L.; Rizopolous, D.; Bodelier, A.; Van Wering, H.; Hurkmans, P.; Stuyt, R.; Hendriks, D.; Van Der Burg, J.; et al. P205 Prevalence and risk factors for anxiety and depressive symptoms in children, adolescents and young adults with inflammatory bowel disease. *J. Crohn's Colitis* **2018**, *12* (Suppl. S1), S202–S203. [\[CrossRef\]](#)
43. Brink, G.V.D.; Stapersma, L.; Vlug, L.E.; Rizopolous, D.; Bodelier, A.G.; van Wering, H.; Hurkmans, P.C.W.M.; Stuyt, R.J.L.; Hendriks, D.M.; van der Burg, J.A.T.; et al. Clinical disease activity is associated with anxiety and depressive symptoms in adolescents and young adults with inflammatory bowel disease. *Aliment. Pharmacol. Ther.* **2018**, *48*, 358–369. [\[CrossRef\]](#)
44. Szigethy, E.; Levy-Warren, A.; Whitton, S.; Bousvaros, A.; Gauvreau, K.; Leichtner, A.M.; Beardslee, W.R. Depressive Symptoms and Inflammatory Bowel Disease in Children and Adolescents: A Cross-Sectional Study. *J. Pediatr. Gastroenterol. Nutr.* **2004**, *39*, 395–403. [\[CrossRef\]](#) [\[PubMed\]](#)
45. Greenley, R.N.; Hommel, K.A.; Nebel, J.; Raboin, T.; Li, S.H.; Simpson, P.; Mackner, L. A meta-analytic review of the psychosocial adjustment of youth with inflammatory bowel disease. *J. Pediatr. Psychol.* **2010**, *35*, 857–869. [\[CrossRef\]](#)
46. Craig, C.F.; Filippone, R.T.; Staveland, R.; Bornstein, J.C.; Apostolopoulos, V.; Nurgali, K. Neuroinflammation as an etiological trigger for depression comorbid with inflammatory bowel disease. *J. Neuroinflamm.* **2022**, *19*, 4. [\[CrossRef\]](#) [\[PubMed\]](#)
47. Keefer, L.; Kane, S.V. Considering the bidirectional pathways between depression and IBD: Recommendations for comprehensive IBD care. *Gastroenterol. Hepatol.* **2017**, *13*, 164–169.
48. Gracie, D.J.; Ford, A.C. Psychological Comorbidity and Inflammatory Bowel Disease Activity: Cause or Effect? *Clin. Gastroenterol. Hepatol.* **2016**, *14*, 1061–1062. [\[CrossRef\]](#)

49. Appleton, J. The Gut-Brain Axis: Influence of Microbiota on Mood and Mental Health. *Integr. Med.* **2018**, *17*, 28–32.
50. Keethy, D.; Mrakotsky, C.; Szigethy, E. Pediatric inflammatory bowel disease and depression: Treatment implications. Current opinion in pediatrics. *Curr. Opin. Pediatr.* **2014**, *26*, 561–567. [[CrossRef](#)]
51. Feldman, E.C.; Durkin, L.K.; Greenley, R.N. Family Support is Associated with Fewer Adherence Barriers and Greater Intent to Adhere to Oral Medications in Pediatric IBD. *J. Pediatr. Nurs.* **2021**, *60*, 58–64. [[CrossRef](#)]
52. Spekhorst, L.M.; Hummel, T.Z.; Benninga, M.A.; van Rheenen, P.F.; Kindermann, A. Adherence to Oral Maintenance Treatment in Adolescents with Inflammatory Bowel Disease. *J. Pediatr. Gastroenterol. Nutr.* **2016**, *62*, 264–270. [[CrossRef](#)]
53. Abraham, B.P.; Kahn, S.A. Transition of Care in Inflammatory Bowel Disease. *Gastroenterol. Hepatol.* **2014**, *10*, 633–640.
54. Turkel, S.; Pao, M. Late Consequences of Chronic Pediatric Illness. *Psychiatr. Clin. N. Am.* **2007**, *30*, 819–835. [[CrossRef](#)] [[PubMed](#)]
55. Lica, M.; Papai, A.; Salcudean, A.; Crainic, M.; Covaciu, C.; Mihai, A. Assessment of Psychopathology in Adolescents with Insulin-Dependent Diabetes (IDD) and the Impact on Treatment Management. *Children* **2021**, *8*, 414. [[CrossRef](#)] [[PubMed](#)]
56. Day, A.; Whitten, K.; Bohane, T. Childhood inflammatory bowel disease: Parental concerns and expectations. *World J. Gastroenterol.* **2005**, *11*, 1028–1031. [[CrossRef](#)]
57. Diederer, K.; Haverman, L.; Grootenhuis, M.A.; Benninga, M.A.; Kindermann, A. Parental Distress and Quality of Life in Pediatric Inflammatory Bowel Disease: Implications for the Outpatient Clinic. *J. Pediatr. Gastroenterol. Nutr.* **2018**, *66*, 630–636. [[CrossRef](#)] [[PubMed](#)]
58. De Boer, M.; Grootenhuis, M.; Derkx, B.; Last, B. Health-related quality of life and psychosocial functioning of adolescents with inflammatory bowel disease. *Inflamm. Bowel. Dis.* **2005**, *11*, 400–406. [[CrossRef](#)] [[PubMed](#)]
59. Assa, A.; Ish-Tov, A.; Rinawi, F.; Shamir, R. School Attendance in Children with Functional Abdominal Pain and Inflammatory Bowel Diseases. *J. Pediatr. Gastroenterol. Nutr.* **2015**, *61*, 553–557. [[CrossRef](#)]
60. Eloi, C.; Foulon, G.; Bridoux-Henno, L.; Breton, E.; Pelatan, C.; Chaillou, E.; Grimal, I.; Darviot, E.; Carré, E.; Gastineau, S.; et al. Inflammatory Bowel Diseases and School Absenteeism. *J. Pediatr. Gastroenterol. Nutr.* **2019**, *68*, 541–546. [[CrossRef](#)]
61. Engström, I. Mental Health and Psychological Functioning in Children and Adolescents with Inflammatory Bowel Disease: A Comparison with Children having Other Chronic Illnesses and with Healthy Children. *J. Child Psychol. Psychiatry* **1992**, *33*, 563–582. [[CrossRef](#)]
62. Manzari, Z.S.; Mohsenizadeh, S.M.; Vosoghina, H.; Ebrahimipour, H. Family caregivers' burden in inflammatory bowel diseases: An integrative review. *J. Educ. Health Promot.* **2020**, *9*, 289. [[CrossRef](#)]
63. van Gennep, S.; de Boer, N.K.H.; Gielen, M.E.; Rietdijk, S.T.; Gecse, K.B.; Ponsioen, C.Y.; Duijvestein, M.; D'Haens, G.R.; Löwenberg, M.; de Boer, A.G.E.M. Impaired Quality of Working Life in Inflammatory Bowel Disease Patients. *Dig. Dis. Sci.* **2020**, *66*, 2916–2924. [[CrossRef](#)] [[PubMed](#)]
64. De Boer, A.G.; Evertsz', F.B.; Stokkers, P.C.; Bockting, C.L.; Sanderma, R.; Hommes, D.W.; Sprangers, M.A.; Frings-Dresen, M.H. Employment status, difficulties at work and quality of life in inflammatory bowel disease patients. *Eur. J. Gastroenterol. Hepatol.* **2016**, *28*, 1130–1136. [[CrossRef](#)] [[PubMed](#)]
65. Karve, S.; Candrilli, S.; Kappelman, M.D.; Tolleson-Rinehart, S.; Tennis, P.; Andrews, E. Healthcare Utilization and Comorbidity Burden among Children and Young Adults in the United States with Systemic Lupus Erythematosus or Inflammatory Bowel Disease. *J. Pediatr.* **2012**, *161*, 662–670.e2. [[CrossRef](#)] [[PubMed](#)]
66. Click, B.; Rivers, C.R.; Koutroubakis, I.; Babichenko, D.; Anderson, A.; Hashash, J.G.; Dunn, M.A.; Schwartz, M.; Swoger, J.; Baidoo, L.; et al. Demographic and Clinical Predictors of High Healthcare Use in Patients with Inflammatory Bowel Disease. *Inflamm. Bowel Dis.* **2016**, *22*, 1442–1449. [[CrossRef](#)] [[PubMed](#)]
67. Carlsen, K.; Haddad, N.; Gordon, J.; Phan, B.L.; Pittman, N.; Benkov, K.; Dubinsky, M.C.; Keefer, L. Self-efficacy and Resilience Are Useful Predictors of Transition Readiness Scores in Adolescents with Inflammatory Bowel Diseases. *Inflamm. Bowel Dis.* **2017**, *23*, 341–346. [[CrossRef](#)]
68. Regueiro, M.D.; McAnallen, S.E.; Greer, J.B.; Perkins, S.E.; Ramalingam, S.; Szigethy, E. The Inflammatory Bowel Disease Specialty Medical Home: A new model of patient-centered care. *Inflamm. Bowel Dis.* **2016**, *22*, 1971–1980. [[CrossRef](#)]
69. Gray, W.N.; Holbrook, E.; Morgan, P.J.; Saeed, S.A.; Denson, L.A.; Hommel, K.A. Transition readiness skills acquisition in adolescents and young adults with inflammatory bowel disease: Findings from integrating assessment into clinical practice. *Inflamm. Bowel Dis.* **2015**, *21*, 1125–1131. [[CrossRef](#)] [[PubMed](#)]
70. Klostermann, N.R.; McAlpine, L.; Wine, E.; Goodman, K.J.; Kroeker, K.I. Assessing the Transition Intervention Needs of Young Adults with Inflammatory Bowel Diseases. *J. Pediatr. Gastroenterol. Nutr.* **2018**, *66*, 281–285. [[CrossRef](#)]
71. Feingold, J.; Murray, H.B.; Keefer, L. Recent Advances in Cognitive Behavioral Therapy for Digestive Disorders and the Role of Applied Positive Psychology Across the Spectrum of GI Care. *J. Clin. Gastroenterol.* **2019**, *53*, 477–485. [[CrossRef](#)]
72. Scheier, M.F.; Carver, C.S. Optimism, coping, and health: Assessment and implications of generalized outcome expectancies. *Health Psychol.* **1985**, *4*, 219–247. [[CrossRef](#)]
73. Komase, Y.; Watanabe, K.; Hori, D.; Nozawa, K.; Hidaka, Y.; Iida, M.; Imamura, K.; Kawakami, N. Effects of gratitude intervention on mental health and well-being among workers: A systematic review. *J. Occup. Health* **2021**, *63*, e12290. [[CrossRef](#)]
74. Thoits, P.A.; Hewitt, L.N. Volunteer Work and Well-Being. *J. Health Soc. Behav.* **2001**, *42*, 115–131. [[CrossRef](#)]
75. Bailey, R.R. Goal Setting and Action Planning for Health Behavior Change. *Am. J. Lifestyle Med.* **2017**, *13*, 615–618. [[CrossRef](#)]
76. Keefer, L.; Palsson, O.S.; Pandolfino, J.E. Best Practice Update: Incorporating Psychogastroenterology Into Management of Digestive Disorders. *Gastroenterology* **2018**, *154*, 1249–1257. [[CrossRef](#)]

77. Ge, L.; Liu, S.; Li, S.; Yang, J.; Hu, G.; Xu, C.; Song, W. Psychological stress in inflammatory bowel disease: Psychoneuroimmunological insights into bidirectional gut–brain communications. *Front. Immunol.* **2022**, *13*, 1016578. [[CrossRef](#)] [[PubMed](#)]
78. Günther, C.; Rothhammer, V.; Karow, M.; Neurath, M.F.; Winner, B. The Gut-Brain Axis in Inflammatory Bowel Disease—Current and Future Perspectives. *Int. J. Mol. Sci.* **2021**, *22*, 8870. [[CrossRef](#)]
79. Masanetz, R.K.; Winkler, J.; Winner, B.; Günther, C.; Süß, P. The Gut–Immune–Brain Axis: An Important Route for Neuropsychiatric Morbidity in Inflammatory Bowel Disease. *Int. J. Mol. Sci.* **2022**, *23*, 11111. [[CrossRef](#)] [[PubMed](#)]
80. Zhang, Y.Z.; Li, Y.Y. Inflammatory bowel disease: Pathogenesis. *World J. Gastroenterol.* **2014**, *20*, 91–99. [[CrossRef](#)]
81. Troubat, R.; Barone, P.; Leman, S.; Desmidt, T.; Cressant, A.; Atanasova, B.; Brizard, B.; El Hage, W.; Surget, A.; Belzung, C.; et al. Neuroinflammation and depression: A review. *Eur. J. Neurosci.* **2021**, *53*, 151–171. [[CrossRef](#)]
82. Brites, D.; Fernandes, A. Neuroinflammation and Depression: Microglia Activation, Extracellular Microvesicles and microRNA Dysregulation. *Front. Cell. Neurosci.* **2015**, *9*, 476. [[CrossRef](#)] [[PubMed](#)]
83. Bonaz, B. Inflammatory bowel diseases: A dysfunction of brain-gut interactions? *Minerva Gastroenterol. Dietol.* **2013**, *59*, 241–259. [[CrossRef](#)]
84. Sublette, M.E.; Postolache, T.T. Neuroinflammation and depression: The role of indoleamine 2,3-dioxygenase (IDO) as a molecular pathway. *Psychosom. Med.* **2012**, *74*, 668–672. [[CrossRef](#)] [[PubMed](#)]
85. Eisch, A.J.; Petrik, D. Depression and hippocampal neurogenesis: A road to remission? *Science* **2012**, *338*, 72–75. [[CrossRef](#)] [[PubMed](#)]
86. Trujillo-Hernández, P.E.; Sáenz-Galindo, A.; Saucedo-Cárdenas, O.; Villarreal-Reyna, M.D.L.; Salinas-Santander, M.A.; Carrillo-Cervantes, A.L.; Torres-Obregón, R.; Esparza-González, S.C. Depressive Symptoms are Associated with low Serotonin Levels in Plasma but are not 5-HTTLPR Genotype Dependent in Older Adults. *Span. J. Psychol.* **2021**, *24*, e28. [[CrossRef](#)] [[PubMed](#)]
87. Moroianu, L.-A.; Cecilia, C.; Ardeleanu, V.; Stoian, A.P.; Cristescu, V.; Barbu, R.-E.; Moroianu, M. Clinical Study of Serum Serotonin as a Screening Marker for Anxiety and Depression in Patients with Type 2 Diabetes. *Medicina* **2022**, *58*, 652. [[CrossRef](#)]
88. Bonaz, B.L.; Bernstein, C.N. Brain-Gut Interactions in Inflammatory Bowel Disease. *Gastroenterology* **2013**, *144*, 36–49. [[CrossRef](#)] [[PubMed](#)]
89. Agostini, A.; Benuzzi, F.; Filippini, N.; Bertani, A.; Scarcelli, A.; Farinelli, V.; Marchetta, C.; Calabrese, C.; Rizzello, F.; Gionchetti, P.; et al. New insights into the brain involvement in patients with Crohn’s disease: A voxel-based morphometry study. *Neurogastroenterol. Motil.* **2012**, *25*, 147–e82. [[CrossRef](#)] [[PubMed](#)]
90. Vogt, B.A. Midcingulate cortex: Structure, connections, homologies, functions and diseases. *J. Chem. Neuroanat.* **2016**, *74*, 28–46. [[CrossRef](#)]
91. Drevets, W.C.; Savitz, J.; Trimble, M. The Subgenual Anterior Cingulate Cortex in Mood Disorders. *CNS Spectr.* **2008**, *13*, 663–681. [[CrossRef](#)]
92. Drevets, W.C.; Price, J.L.; Simpson, J.R., Jr.; Todd, R.D.; Reich, T.; Vannier, M.; Raichle, M.E. Subgenual prefrontal cortex abnormalities in mood disorders. *Nature* **1997**, *386*, 824–827. [[CrossRef](#)]
93. Rolls, E.T. The cingulate cortex and limbic systems for action, emotion, and memory. *Handb. Clin. Neurol.* **2019**, *166*, 23–37. [[CrossRef](#)] [[PubMed](#)]
94. Bao, C.H.; Liu, P.; Liu, H.R.; Wu, L.Y.; Shi, Y.; Chen, W.F.; Qin, W.; Lu, Y.; Zhang, J.Y.; Jin, X.M.; et al. Alterations in Brain Grey Matter Structures in Patients With Crohn’s Disease and Their Correlation With Psychological Distress. *J. Crohn’s Colitis* **2015**, *9*, 532–540. [[CrossRef](#)] [[PubMed](#)]
95. Hopkins, C.W.; Powell, N.; Norton, C.; Dumbrill, J.L.; Hayee, B.; Moulton, C.D. Cognitive Impairment in Adult Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. *J. Acad. Consult.-Liaison Psychiatry* **2021**, *62*, 387–403. [[CrossRef](#)] [[PubMed](#)]
96. Piasecki, B.; Stanisławska-Kubiak, M.; Strzelecki, W.; Mojs, E. Attention and Memory Impairments in Pediatric Patients with Cystic Fibrosis and Inflammatory Bowel Disease in Comparison to Healthy Controls. *J. Investig. Med.* **2017**, *65*, 1062–1067. [[CrossRef](#)]
97. Chen, M.; Lee, G.; Kwong, L.N.; Lamont, S.; Chaves, C. Cerebral White Matter Lesions in Patients with Crohn’s Disease. *J. Neuroimaging* **2010**, *22*, 38–41. [[CrossRef](#)]
98. Dolapcioglu, C.; Guleryuzlu, Y.; Uygur-Bayramicli, O.; Ahishali, E.; Dabak, R. Asymptomatic Brain Lesions on Cranial Magnetic Resonance Imaging in Inflammatory Bowel Disease. *Gut Liver* **2013**, *7*, 169–174. [[CrossRef](#)]
99. Horta, E.; Burke-Smith, C.; Megna, B.W.; Nichols, K.J.; Vaughn, B.P.; Reshi, R.; Schmidt, E. Prevalence of cerebrovascular accidents in patients with ulcerative colitis in a single academic health system. *Sci. Rep.* **2022**, *12*, 18668. [[CrossRef](#)]
100. Ghoneim, S.; Shah, A.; Dhorepatil, A.; Butt, M.U.; Waghray, N. The Risk of Cerebrovascular Accidents in Inflammatory Bowel Disease in the United States: A Population-Based National Study. *Clin. Exp. Gastroenterol.* **2020**, *13*, 123–129. [[CrossRef](#)]
101. Mikocka-Walus, A.; Knowles, S.R.; Keefer, L.; Graff, L. Controversies Revisited: A Systematic Review of the Comorbidity of Depression and Anxiety with Inflammatory Bowel Diseases. *Inflamm. Bowel Dis.* **2016**, *22*, 752–762. [[CrossRef](#)]
102. Arp, L.; Jansson, S.; Wewer, V.; Burisch, J. Psychiatric Disorders in Adult and Paediatric Patients with Inflammatory Bowel Diseases—A Systematic Review and Meta-Analysis. *J. Crohn’s Colitis* **2022**, *16*, 1933–1945. [[CrossRef](#)]
103. Bernstein, C.N.; Hitchon, C.A.; Walld, R.; Bolton, J.M.; Sareen, J.; Walker, J.R.; Graff, L.A.; Patten, S.B.; Singer, A.; Lix, L.M.; et al. Increased Burden of Psychiatric Disorders in Inflammatory Bowel Disease. *Inflamm. Bowel Dis.* **2018**, *25*, 360–368. [[CrossRef](#)] [[PubMed](#)]

104. Nahon, S.; Lahmek, P.; Durance, C.; Olympie, A.; Lesgourgues, B.; Colombel, J.-F.; Gendre, J.-P. Risk factors of anxiety and depression in inflammatory bowel disease. *Inflamm. Bowel Dis.* **2012**, *18*, 2086–2091. [CrossRef]
105. Sempere, L.; Bernabeu, P.; Cameo, J.; Gutierrez, A.; Laveda, R.; Garcia, M.F.; Aguas, M.; Zapater, P.; Jover, R.; Ruiz-Cantero, M.T.; et al. Evolution of the emotional impact in patients with early inflammatory bowel disease during and after COVID-19 lockdown. *Gastroenterol. Hepatol.* **2021**, *45*, 123–133. [CrossRef]
106. Xiong, Q.; Tang, F.; Li, Y.; Xie, F.; Yuan, L.; Yao, C.; Wu, R.; Wang, J.; Wang, Q.; Feng, P. Association of inflammatory bowel disease with suicidal ideation, suicide attempts, and suicide: A systematic review and meta-analysis. *J. Psychosom. Res.* **2022**, *160*, 110983. [CrossRef] [PubMed]
107. Santa, A.; Szántó, K.J.; Sarlós, P.; Miheller, P.; Farkas, K.; Molnár, T. Letter: Suicide risk among adult inflammatory bowel disease patients. *Aliment. Pharmacol. Ther.* **2020**, *51*, 1213–1214. [CrossRef] [PubMed]
108. Butwicka, A.; Olén, O.; Larsson, H.; Halfvarson, J.; Almqvist, C.; Lichtenstein, P.; Serlachius, E.; Frisén, L.; Ludvigsson, J.F. Association of Childhood-Onset Inflammatory Bowel Disease with Risk of Psychiatric Disorders and Suicide Attempt. *JAMA Pediatr.* **2019**, *173*, 969–978. [CrossRef]
109. Eaton, W.W.; Pedersen, M.G.; Nielsen, P.R.; Mortensen, P.B. Autoimmune diseases, bipolar disorder, and non-affective psychosis. *Bipolar Disord.* **2010**, *12*, 638–646. [CrossRef]
110. Kao, L.-T.; Lin, H.-C.; Lee, H.-C. Inflammatory bowel disease and bipolar disorder: A population-based cross-sectional study. *J. Affect. Disord.* **2019**, *247*, 120–124. [CrossRef]
111. Wang, Z.; Wang, X.; Zhao, X.; Hu, Z.; Sun, D.; Wu, D.; Xing, Y. Causal relationship between bipolar disorder and inflammatory bowel disease: A bidirectional two-sample mendelian randomization study. *Front. Genet.* **2022**, *13*, 970933. [CrossRef] [PubMed]
112. Sung, K.; Zhang, B.; Wang, H.E.; Bai, Y.; Tsai, S.; Su, T.; Chen, T.; Hou, M.; Lu, C.; Wang, Y.; et al. Schizophrenia and risk of new-onset inflammatory bowel disease: A nationwide longitudinal study. *Aliment. Pharmacol. Ther.* **2022**, *55*, 1192–1201. [CrossRef]
113. West, J.; Logan, R.F.; Hubbard, R.B.; Card, T.R. Risk of schizophrenia in people with coeliac disease, ulcerative colitis and Crohn's disease: A general population-based study. *Aliment. Pharmacol. Ther.* **2006**, *23*, 71–74. [CrossRef]
114. Kim, J.W.; Kang, K.S.; Kang, N.R. Steroid-induced Psychosis in Adolescent Patient with Crohn's Disease. *Soach'ongsonyon Chongsin Uihak J. Child Adolesc. Psychiatry* **2020**, *31*, 161–164. [CrossRef] [PubMed]
115. Locher, M.R.; Alam, A. Acute Psychosis in an Adolescent Treated with Infliximab for Crohn's Disease. *Prim. Care Companion J. Clin. Psychiatry* **2015**, *17*, 4. [CrossRef] [PubMed]
116. Galmiche, M.; Déchelotte, P.; Lambert, G.; Tavolacci, M.P. Prevalence of eating disorders over the 2000–2018 period: A systematic literature review. *Am. J. Clin. Nutr.* **2019**, *109*, 1402–1413. [CrossRef] [PubMed]
117. Kuźnicki, P.; Neubauer, K. Emerging Comorbidities in Inflammatory Bowel Disease: Eating Disorders, Alcohol and Narcotics Misuse. *J. Clin. Med.* **2021**, *10*, 4623. [CrossRef]
118. World Health Organization. Suicide Worldwide in 2019: Global Health Estimates. Available online: <https://www.who.int/publications/i/item/9789240026643> (accessed on 8 December 2022).
119. World Health Organization. Report Urges Mental Health Decision Makers and Advocates to Step Up Commitment and Action to Change Attitudes, Actions and Approaches to Mental Health, Its Determinants and Mental Health Care. Available online: <https://www.who.int/news/item/17-06-2022-who-highlights-urgent-need-to-transform-mental-health-and-mental-health-care> (accessed on 8 December 2022).
120. Gradus, J.L.; Qin, P.; Lincoln, A.K.; Miller, M.; Lawler, E.; Sørensen, H.T.; Lash, T.L. Inflammatory bowel disease and completed suicide in Danish adults. *Inflamm. Bowel Dis.* **2010**, *16*, 2158–2161. [CrossRef]
121. Mihajlovic, V.; Tripp, D.A.; Jacobson, J.A. Modelling symptoms to suicide risk in individuals with inflammatory bowel disease. *J. Health Psychol.* **2020**, *26*, 2143–2152. [CrossRef]
122. Moulton, C.; Pavlidis, P.; Norton, C.; Norton, S.; Pariente, C.; Hayee, B.; Powell, N. Depressive symptoms in inflammatory bowel disease: An extraintestinal manifestation of inflammation? *Clin. Exp. Immunol.* **2019**, *197*, 308–318. [CrossRef]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.